Dual Inhibition of Ornithine Decarboxylase and A
A1AR
cyclic AMP (cAMP) pathway
dual inhibitor
ornithine decarboxylase 1 (ODC)
polyamine pathway
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
12
2020
accepted:
03
02
2021
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
30
3
2021
Statut:
epublish
Résumé
Personized treatment of breast cancer is still a challenge, and more treatment options for breast cancer are warranted. Combination therapies have been a highly appreciated strategy for breast cancer treatment in recent years, and the development of new combination therapies could improve patient outcomes. Adenosine and polyamines are both endogenous metabolites with indispensable biological functions. Adenosine binds with the A
Identifiants
pubmed: 33777791
doi: 10.3389/fonc.2021.636373
pmc: PMC7991832
doi:
Types de publication
Journal Article
Langues
eng
Pagination
636373Informations de copyright
Copyright © 2021 Ma, Li, Wang, Pan, Su and Liu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Breast Cancer Res Treat. 2014 Nov;148(2):233-48
pubmed: 25292420
FASEB J. 2020 Sep;34(9):10907-12921
pubmed: 32767470
Front Cell Neurosci. 2019 Mar 28;13:124
pubmed: 30983976
J Transl Med. 2011 Jul 21;9:115
pubmed: 21777474
Carcinogenesis. 2003 May;24(5):869-73
pubmed: 12771030
Sci Transl Med. 2019 Jan 30;11(477):
pubmed: 30700572
Methods Mol Biol. 2018;1694:469-488
pubmed: 29080189
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Biol Chem. 2020 May 8;295(19):6263-6277
pubmed: 32139506
ACS Chem Neurosci. 2013 Mar 20;4(3):454-62
pubmed: 23509981
Cell Physiol Biochem. 2017;43(2):733-742
pubmed: 28950257
Res Pharm Sci. 2016 Jul;11(4):303-10
pubmed: 27651810
Molecules. 2019 Sep 14;24(18):
pubmed: 31540079
Mol Med Rep. 2016 May;13(5):3715-23
pubmed: 27035868
CNS Oncol. 2018 Apr;7(2):CNS16
pubmed: 29378419
Trends Cancer. 2017 Nov;3(11):753-760
pubmed: 29120751
Nat Rev Cancer. 2018 Nov;18(11):681-695
pubmed: 30181570
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Nature. 2019 Apr;568(7751):254-258
pubmed: 30842661
Future Oncol. 2017 Apr;13(9):809-819
pubmed: 28125906
Nature. 2018 Jun;558(7711):559-563
pubmed: 29925945
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Sci Rep. 2015 Jun 01;5:10754
pubmed: 26030749
Cancer Biol Ther. 2009 Jun;8(12):1183-90
pubmed: 19662684
Oncogene. 2010 Feb 25;29(8):1114-22
pubmed: 19935720
J Chem Inf Model. 2016 Aug 22;56(8):1563-75
pubmed: 27411028
Mol Ther. 2016 Feb;24(1):156-65
pubmed: 26373347
Front Pharmacol. 2020 Mar 11;11:248
pubmed: 32218733
J Med Chem. 2018 Nov 21;61(22):9966-9975
pubmed: 30359014
Sci Adv. 2018 Jan 24;4(1):eaar2606
pubmed: 29376126
Front Oncol. 2018 Jun 14;8:227
pubmed: 29963498
Breast Cancer Res Treat. 2012 Nov;136(1):57-66
pubmed: 22976807
Int J Cancer. 2013 Sep 15;133(6):1323-33
pubmed: 23457004
Neurosci Lett. 1991 Apr 1;124(2):183-6
pubmed: 1648689
J Med Chem. 1989 Aug;32(8):1873-9
pubmed: 2754711